Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLM007
MIFTS: 60

Glomerulonephritis

Categories: Blood diseases, Immune diseases, Nephrological diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Glomerulonephritis

About this section

MalaCards integrated aliases for Glomerulonephritis:

Name: Glomerulonephritis 11 19 75 53 5 43 14 36 71
Bright's Disease 19 75

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:2921
MeSH 43 D005921
NCIt 49 C26784
SNOMED-CT 68 36171008
ICD10 31 N08
UMLS 71 C0017658
Sources

Summaries for Glomerulonephritis

About this section

GARD: 19 Glomerulonephritis is a type of kidney disease in which there is inflammation of the glomeruli, the tiny filters that remove excess waste and fluids from the blood. It may be acute or chronic (coming on gradually), and may occur on its own (primary) or be caused by another condition (secondary). Signs and symptoms may depend on the type and cause of the condition and may include blood in the urine; foamy urine; swelling of the face, eyes, or other body parts; abdominal pain; high blood pressure; fatigue; and/or other symptoms. If the condition is severe or prolonged, the kidneys can become damaged. It may be caused by a variety of infections and diseases, and sometimes the cause is unknown.

MalaCards based summary: Glomerulonephritis, also known as bright's disease, is related to c3 glomerulopathy and membranous nephropathy. An important gene associated with Glomerulonephritis is COL4A4 (Collagen Type IV Alpha 4 Chain), and among its related pathways/superpathways are Innate Immune System and Defects of contact activation system (CAS) and kallikrein/kinin system (KKS). The drugs Leflunomide and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include Kidney, heart and bone marrow, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology: 11 A nephritis that causes inflammation of the glomeruli located in kidney.

Wikipedia 75 Glomerulonephritis: Glomerulonephritis (GN) is a term used to refer to several kidney diseases (usually affecting both... more...

Bright's disease: Bright's disease is a historical classification of kidney diseases that are described in modern medicine... more...
Sources

Related Diseases for Glomerulonephritis

About this section

Diseases in the Glomerulonephritis family:

Autoimmune Glomerulonephritis Subacute Glomerulonephritis

Diseases related to Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1410)
# Related Disease Score Top Affiliating Genes
1 c3 glomerulopathy 33.4 CFHR5 CFH C3
2 membranous nephropathy 33.2 NPHS2 NPHS1 LRP2 CR1 CD79A CCL2
3 mesangial proliferative glomerulonephritis 33.2 NPHS2 NPHS1 CD79A CCL2 C3 ALB
4 iga glomerulonephritis 33.1 PRTN3 NPHS2 NPHS1 CFHR5 CFH CD79A
5 acute proliferative glomerulonephritis 33.0 PRTN3 NPHS2 NPHS1 MPO COL4A3 CCL2
6 rapidly progressive glomerulonephritis 33.0 PRTN3 NPHS1 MPO COL4A4 COL4A3 C3
7 proliferative glomerulonephritis 32.9 PRTN3 MPO CFH CD79A CCL2 C3
8 goodpasture syndrome 32.9 PRTN3 NPHS1 MPO COL4A5 COL4A4 COL4A3
9 acute poststreptococcal glomerulonephritis 32.9 CFHR5 CFH CD79A C3 ALB
10 membranoproliferative glomerulonephritis 32.8 PRTN3 NPHS2 NPHS1 MPO CR1 CFI
11 immune-complex glomerulonephritis 32.8 PRTN3 CFH C3 ALB
12 crescentic glomerulonephritis 32.8 PRTN3 NPHS2 NPHS1 MPO COL4A3 CCL2
13 systemic lupus erythematosus 32.5 PRTN3 MPO CR1 CFI CFH CD79A
14 anti-basement membrane glomerulonephritis 32.5 PRTN3 MPO COL4A5 COL4A4 COL4A3 C3
15 henoch-schoenlein purpura 32.5 PRTN3 MPO CD79A C3 ALB
16 lipoid nephrosis 32.3 NPHS2 NPHS1 CD79A CCL2 APOL1 ALB
17 vasculitis 32.2 PRTN3 MPO CD79A CCL2 C3
18 complement factor i deficiency 32.2 CR1 CFI C4B C4A C3
19 hypersensitivity vasculitis 32.2 PRTN3 MPO CD79A C3 ALB
20 complement component 3 deficiency 32.0 CR1 CFI CFH C4B C4A C3
21 alport syndrome 2, autosomal recessive 31.9 COL4A4 COL4A3
22 acute kidney failure 31.9 PRTN3 CFH ALB
23 alport syndrome 3, autosomal dominant 31.9 COL4A5 COL4A4 COL4A3
24 autosomal recessive alport syndrome 31.9 NPHS2 NPHS1 COL4A5 COL4A4 COL4A3 CFHR5
25 autosomal dominant alport syndrome 31.9 NPHS2 COL4A5 COL4A4 COL4A3 CFHR5
26 lupus erythematosus 31.8 CR1 C4B C4A C3 C1QC
27 autoimmune disease 31.8 PRTN3 CD79A CCL2 C4B C4A
28 nephrotic syndrome 31.7 NPHS2 NPHS1 MPO LRP2 COL4A5 COL4A4
29 alport syndrome 31.7 NPHS2 NPHS1 LRP2 COL4A5 COL4A4 COL4A3
30 chronic kidney disease 31.7 NPHS2 NPHS1 COL4A5 COL4A4 CFI CFH
31 infective endocarditis 31.7 PRTN3 MPO ALB
32 kidney disease 31.6 PRTN3 NPHS2 NPHS1 LRP2 COL4A5 COL4A4
33 microscopic polyangiitis 31.6 PRTN3 MPO
34 end stage renal disease 31.6 COL4A5 COL4A4 COL4A3 CFI CFHR5 CFH
35 focal segmental glomerulosclerosis 5 31.5 NPHS2 APOL1
36 hemolytic-uremic syndrome 31.4 CFI CFHR5 CFH C4B C3
37 exanthem 31.4 PRTN3 MPO ALB
38 focal segmental glomerulosclerosis 31.4 NPHS2 NPHS1 CR1 COL4A5 COL4A4 COL4A3
39 hypersensitivity reaction type iii disease 31.3 PRTN3 MPO CR1 CD79A C4B C4A
40 hemolytic anemia 31.3 CR1 CFI CFHR5 CFH C3 ALB
41 syphilis 31.3 PRTN3 CD79A ALB
42 nephrosclerosis 31.3 NPHS2 NPHS1 MPO CCL2
43 idiopathic nephrotic syndrome 31.3 NPHS2 NPHS1
44 hemolytic uremic syndrome, atypical 1 31.2 CR1 COL4A5 CFI CFHR5 CFH C4B
45 interstitial nephritis 31.2 PRTN3 APOL1 ALB
46 d-minus hemolytic uremic syndrome 31.2 COL4A5 CFI CFHR5 CFH C3
47 proteasome-associated autoinflammatory syndrome 1 31.1 MPO CCL2 ALB
48 thrombocytopenia 31.1 CFI CFHR5 CFH CD79A CCL2 C3
49 subacute bacterial endocarditis 31.1 PRTN3 MPO ALB
50 pulmonary hemosiderosis 31.1 PRTN3 MPO

Graphical network of the top 20 diseases related to Glomerulonephritis:



Diseases related to Glomerulonephritis
Sources

Symptoms & Phenotypes for Glomerulonephritis

About this section

GenomeRNAi Phenotypes related to Glomerulonephritis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 ALB C1QC C3 C4A CCL2 CD79A

MGI Mouse Phenotypes related to Glomerulonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 ALB C1QC C3 C4A C4B CCL2
2 renal/urinary system MP:0005367 10.21 ALB C3 C4A C4B CD79A CFH
3 cardiovascular system MP:0005385 10.07 ALB APOL1 C3 C4A C4B CCL2
4 immune system MP:0005387 10.03 ALB C3 C4A C4B CCL2 CD79A
5 hematopoietic system MP:0005397 9.8 C3 C4A C4B CCL2 CD79A CFH
6 mortality/aging MP:0010768 9.5 ALB C3 C4A C4B CCL2 CD79A
Sources

Drugs & Therapeutics for Glomerulonephritis

About this section

Drugs for Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 224)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
4
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
5
Probucol Approved, Investigational Phase 4 23288-49-5 4912
6
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
9
Rituximab Approved Phase 4 174722-31-7
10
Losartan Approved Phase 4 114798-26-4 3961
11
Ramipril Approved Phase 4 87333-19-5 5362129
12
Canagliflozin Approved Phase 4 842133-18-0 74323022 24812758
13
Dapagliflozin Approved Phase 4 461432-26-8 9887712
14
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
15
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
16
Azathioprine Approved Phase 4 446-86-6 2265
17
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
18
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
19
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
20
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
22
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
23
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
24
Basiliximab Approved, Investigational Phase 4 179045-86-4
25
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
26
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
27
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
28
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
29 Mitogens Phase 4
30 interferons Phase 4
31 Interferon-alpha Phase 4
32 Cassava Phase 4
33 HIV Protease Inhibitors Phase 4
34
protease inhibitors Phase 4
35 Anticholesteremic Agents Phase 4
36 Omega 3 Fatty Acid Phase 4
37 Vitamins Phase 4
38 Trace Elements Phase 4
39 Vasoconstrictor Agents Phase 4
40 Calcium, Dietary Phase 4
41 Micronutrients Phase 4
42 Antiprotozoal Agents Phase 4
43 Antiparasitic Agents Phase 4
44 Antimalarials Phase 4
45 Proteasome Inhibitors Phase 4
46 Angiotensin-Converting Enzyme Inhibitors Phase 4
47 Pharmaceutical Solutions Phase 4
48 Antiemetics Phase 4
49 Immunosuppressive Agents Phase 4
50 Alkylating Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 277)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency Unknown status NCT04020328 Phase 4 Leflunomide 20 mg+prednisone 0.5mg/kg/d
2 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
3 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
4 The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis : A Multicenter, Prospective, Randomized, Controlled, Single-blind Trial. Unknown status NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
5 Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis：A Multicenter Randomized Controlled Clinical Trial Unknown status NCT04349683 Phase 4 Jinshuibao;Placebo
6 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
7 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
8 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
9 A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
10 An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy Unknown status NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
11 A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
12 A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Unknown status NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
13 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
14 Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Completed NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
15 A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
16 Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
17 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
18 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
19 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
20 Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
21 Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy Completed NCT03025828 Phase 4 ACTHar
22 To Compare the Efficacy and Safety of TW vs Valsartan in the MN Completed NCT00518219 Phase 4 TW
23 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
24 Multitarget Therapy for Idiopathic Membranous Nephropathy Completed NCT04424862 Phase 4 Prednisone, ciclosporin and mycophenolate mofetil;Ponticelli Regimen
25 Velcade Therapy for Severe IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
26 Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study Completed NCT00922311 Phase 4 Aliskiren
27 The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy Completed NCT00319761 Phase 4 Calcitriol
28 Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
29 A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
30 Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis: A Multicentre Prospective, Randomized, Double-blind and Imitation, Positive-drug Parallel Controlled Clinical Trail Recruiting NCT04263922 Phase 4 Huaiqihuang granules;Valsartan capsule
31 A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy Recruiting NCT04525729 Phase 4 Rituximab;RAS 2410
32 A Multicenter, Comparative Safety and Efficacy Study of ACTHar Gel Alone or in Combination With Oral Tacrolimus to Reduce Urinary Proteinuria in Patients With Idiopathic DNAJB9 Positive Fibrillary Glomerulopathy Active, not recruiting NCT05546047 Phase 4 Acthar Gel 80 UNT/ML Injectable Solution
33 Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Not yet recruiting NCT04662723 Phase 4 Corticosteroid;Renin-angiotensin sytem blockers;Sodium-glucose cotransporter 2 inhibitor
34 Clinical Study of Rituximab or Cyclophosphamide Combined With Steroids in the Treatment of Idiopathic Membranous Nephropathy Not yet recruiting NCT05514015 Phase 4 Rituximab;Cyclophosphamide
35 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
36 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
37 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Terminated NCT02523768 Phase 4 ATG-F;Simulect
38 An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
39 Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
40 A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Unknown status NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
41 Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis Unknown status NCT03180723 Phase 3 Rituximab;Cyclosporin
42 A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
43 A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients Unknown status NCT03357653 Phase 3 Losartan group;Placebo group
44 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy -- A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside
45 Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
46 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
47 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membranous Nephritis Completed NCT00404794 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and tacrolimus
48 Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy Completed NCT00135954 Phase 3 Cyclophosphamide and steroids
49 Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study Completed NCT00135967 Phase 2, Phase 3 mycophenolate mofetil orally 1000 mg twice a day (BID);prednisone 0,5 mg/kg orally on alternate days;intravenous (i.v.) methylprednisolone 1000 mg, total 9
50 A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy Completed NCT02232776 Phase 3 Losartan

Search NIH Clinical Center for Glomerulonephritis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Glomerulonephritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Glomerulonephritis:
Mesenchymal stromal cells for glomerulonephritis
Embryonic/Adult Cultured Cells Related to Glomerulonephritis:
Bone marrow-derived mesenchymal stromal cells PMIDs: 22172807

Cochrane evidence based reviews: glomerulonephritis

Sources

Genetic Tests for Glomerulonephritis

About this section
Sources

Anatomical Context for Glomerulonephritis

About this section

Organs/tissues related to Glomerulonephritis:

FMA: Kidney
MalaCards : Kidney, Heart, Bone Marrow, T Cells, Neutrophil, Liver, B Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Glomerulonephritis:
# Tissue Anatomical CompartmentCell Relevance
1 Kidney Glomerulus Affected by disease
Sources

Publications for Glomerulonephritis

About this section

Articles related to Glomerulonephritis:

(show top 50) (show all 29524)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
2
COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. 5
24052634 2013
3
Nine novel COL4A3 and COL4A4 mutations and polymorphisms identified in inherited membrane diseases. 5
17216251 2007
4
Three novel COL4A4 mutations resulting in stop codons and their clinical effects in autosomal recessive Alport syndrome. 5
12325029 2002
5
Suppression of nephrin expression by TNF-alpha via interfering with the cAMP-retinoic acid receptor pathway. 53 62
20237236 2010
6
Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation. 53 62
20155828 2010
7
T cells, adhesion molecules and modulation of apoptosis in visceral leishmaniasis glomerulonephritis. 53 62
20459816 2010
8
Autoimmune kidney diseases. 53 62
19906361 2010
9
Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. 53 62
20042261 2010
10
Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis. 53 62
19898926 2010
11
Ameliorative effects of arctiin from Arctium lappa on experimental glomerulonephritis in rats. 53 62
19524415 2009
12
[Expression of MCP-1 in renal tissues of patients with IgA nephropathy]. 53 62
19893256 2009
13
Parallel genotyping of 10,204 single nucleotide polymorphisms to screen for susceptible genes for IgA nephropathy. 53 62
19890582 2009
14
Hepatitis B virus associated focal and segmental glomerular sclerosis: report of two cases and review of literature. 53 62
19169768 2009
15
Analyzing antibody activity in IgA nephropathy. 53 62
19504718 2009
16
Resolution of IgM nephropathy after rituximab treatment. 53 62
19084309 2009
17
Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. 53 62
19067130 2009
18
Molecular heterogeneity of urinary albumin in glomerulonephritis: comparison of cardiovascular disease with albuminuria. 53 62
19150611 2009
19
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. 53 62
19264905 2009
20
Vasculitic IgA nephropathy: prognosis and outcome. 53 62
19342865 2009
21
Transforming growth factor-beta 1 in Balkan endemic nephropathy. 53 62
19147994 2009
22
Glomerular diseases in a Hispanic population: review of a regional renal biopsy database. 53 62
19820874 2009
23
[MPO-positive cells and extracellular MPO in the glomeruli of MPO-ANCA-associated glomerulonephritis]. 53 62
19238910 2009
24
Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis. 53 62
19587833 2009
25
A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe. 53 62
19210866 2008
26
The protective role of uteroglobin through the modulation of tissue transglutaminase in the experimental crescentic glomerulonephritis. 53 62
18558621 2008
27
Valvular injury in a patient with PR3-ANCA-associated glomerulonephritis. 53 62
18762796 2008
28
Antigenic heterogeneity of IgA anti-GBM disease: new renal targets of IgA autoantibodies. 53 62
18752876 2008
29
Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. 53 62
18725016 2008
30
[Crohn's disease in association with IgA nephropathy]. 53 62
19077504 2008
31
IgA nephropathy: lessons from an animal model, the ddY mouse. 53 62
18651534 2008
32
Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis. 53 62
18462998 2008
33
Increased plasma acylation-stimulating protein in pediatric proteinuric renal disease. 53 62
18253759 2008
34
Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. 53 62
18538590 2008
35
Scleroderma with crescentic glomerulonephritis: a case report. 53 62
18474117 2008
36
Smad7 as a therapeutic agent for chronic kidney diseases. 53 62
18508563 2008
37
Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. 53 62
18371543 2008
38
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis. 53 62
18497456 2008
39
Should a renal biopsy be performed at the first relapse of 'clinical nephrotic syndrome'? 53 62
18365928 2008
40
Role of macrophage migration inhibition factor in kidney disease. 53 62
18663334 2008
41
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. 53 62
18925530 2008
42
Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. 53 62
17914026 2008
43
Remission of proteinuria improves prognosis in IgA nephropathy. 53 62
17978307 2007
44
Intramolecular epitope spreading in Heymann nephritis. 53 62
18003776 2007
45
The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. 53 62
18055544 2007
46
Chemically modified siRNA prolonged RNA interference in renal disease. 53 62
17880921 2007
47
Streptococcal exotoxin B increases interleukin-6, tumor necrosis factor alpha, interleukin-8 and transforming growth factor beta-1 in leukocytes. 53 62
17530297 2007
48
Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome). 53 62
17655694 2007
49
Lack of association between NPHS2 gene polymorphisms and sporadic IgA nephropathy. 53 62
17635752 2007
50
Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. 53 62
17342176 2007
Sources

Variations for Glomerulonephritis

About this section

ClinVar genetic disease variations for Glomerulonephritis:

5 (show all 12)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 APOL1 NM_003661.4(APOL1):c.1024A>G (p.Ser342Gly) SNV Pathogenic
 277678 rs73885319 GRCh37: 22:36661906-36661906
GRCh38: 22:36265860-36265860
2 APOL1 NM_003661.4(APOL1):c.1152T>G (p.Ile384Met) SNV Pathogenic
 127198 rs60910145 GRCh37: 22:36662034-36662034
GRCh38: 22:36265988-36265988
3 COL4A4 NM_000092.5(COL4A4):c.2638del (p.Ala880fs) DEL Pathogenic
 550471 rs778043831 GRCh37: 2:227920739-227920739
GRCh38: 2:227056023-227056023
4 COL4A4 NM_000092.5(COL4A4):c.854G>A (p.Gly285Glu) SNV Likely Pathogenic
 930185 rs2060621902 GRCh37: 2:227967876-227967876
GRCh38: 2:227103160-227103160
5 COL4A4 NM_000092.5(COL4A4):c.788C>G (p.Pro263Arg) SNV Uncertain Significance
 930186 rs369108674 GRCh37: 2:227968716-227968716
GRCh38: 2:227104000-227104000
6 COL4A4 NM_000092.5(COL4A4):c.1246C>G (p.Pro416Ala) SNV Uncertain Significance
 930187 rs372841765 GRCh37: 2:227958964-227958964
GRCh38: 2:227094248-227094248
7 LAMB2 NM_002292.4(LAMB2):c.4307G>A (p.Arg1436His) SNV Uncertain Significance
 930193 rs377526198 GRCh37: 3:49160403-49160403
GRCh38: 3:49122970-49122970
8 MYH9 NM_002473.6(MYH9):c.5185G>T (p.Ala1729Ser) SNV Uncertain Significance
 499790 rs140662138 GRCh37: 22:36681793-36681793
GRCh38: 22:36285747-36285747
9 NPHS1 NM_004646.4(NPHS1):c.2344G>A (p.Glu782Lys) SNV Uncertain Significance
 930197 rs549487912 GRCh37: 19:36333443-36333443
GRCh38: 19:35842541-35842541
10 PLCE1 NM_016341.4(PLCE1):c.756G>T (p.Gln252His) SNV Uncertain Significance
 930200 rs781693565 GRCh37: 10:95791559-95791559
GRCh38: 10:94031802-94031802
11 INF2 NM_022489.4(INF2):c.2054T>C (p.Ile685Thr) SNV Uncertain Significance
 1210229 GRCh37: 14:105175958-105175958
GRCh38: 14:104709621-104709621
12 CEL NM_001807.6(CEL):c.1966G>C (p.Ala656Pro) SNV Uncertain Significance
 128688 rs587780309 GRCh37: 9:135946855-135946855
GRCh38: 9:133071468-133071468

Copy number variations for Glomerulonephritis from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21052 1 156500000 165500000 Copy number FCGR3A Glomerulonephritis
2 21055 1 156500000 165500000 Loss FCGR3B Glomerulonephritis
3 21056 1 156500000 165500000 Low copy number FCGR3B Glomerulonephritis
Sources

Expression for Glomerulonephritis

About this section
Search GEO for disease gene expression data for Glomerulonephritis.
Sources

Pathways for Glomerulonephritis

About this section

Pathways related to Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.81 C1QC C3 C4A C4B CCL2 CD79A
2
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) 66
Show member pathways
 12.33 PRTN3 CR1 CFI CFH C4B C3
3
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
Show member pathways
 12.2 C4B C4A C3 APOL1 ALB
4
Complement cascade 66
Show member pathways
 11.88 LRP2 CR1 CFI CFHR5 CFH C4B
5
Initial triggering of complement 66
Show member pathways
 11.86 C1QC C3 C4A C4B CFH
6
NCAM signaling for neurite out-growth 66
Show member pathways
 11.76 COL4A5 COL4A4 COL4A3
7
Allograft rejection 74
11.73 C4B C4A C3 C1QC
8
Small cell lung cancer 74
11.71 COL4A5 COL4A4 COL4A3
9
Signaling by PDGF 66
Show member pathways
 11.65 COL4A5 COL4A4 COL4A3
10
Extrafollicular B cell activation by SARS-CoV-2 74
11.62 CR1 CD79A C4B C4A C3
11
Primary focal segmental glomerulosclerosis (FSGS) 74
11.59 NPHS2 NPHS1 CR1 COL4A5 COL4A4 COL4A3
12
Immune response Lectin induced complement pathway 22
Show member pathways
 11.53 CR1 CFI CFH C4B C4A C3
13
Cell adhesion_ECM remodeling 22
11.47 COL4A5 COL4A4 COL4A3
14
Cell adhesion_Plasmin signaling 22
11.36 COL4A5 COL4A4 COL4A3
15
Nephrotic syndrome 74
11.31 APOL1 COL4A3 COL4A4 COL4A5 NPHS1 NPHS2
16
LDL Oxidation in Atherogenesis 64
10.77 MPO CCL2
17
Vitamin B12 metabolism 74
10.48 LRP2 CCL2
Sources

GO Terms for Glomerulonephritis

About this section

Cellular components related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.48 PRTN3 NPHS2 NPHS1 MPO LRP2 CR1
2 extracellular region GO:0005576 10.33 ALB APOL1 C1QC C3 C4A C4B
3 endoplasmic reticulum lumen GO:0005788 10.1 COL4A5 COL4A4 COL4A3 C4A C3 APOL1
4 extracellular space GO:0005615 9.83 ALB APOL1 C1QC C3 C4A C4B
5 collagen type IV trimer GO:0005587 9.8 COL4A3 COL4A4 COL4A5
6 blood microparticle GO:0072562 9.8 ALB APOL1 C1QC C3 C4A C4B
7 collagen trimer GO:0005581 9.77 COL4A5 COL4A4 COL4A3 C1QC
8 slit diaphragm GO:0036057 9.73 NPHS2 NPHS1

Biological processes related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.22 CR1 CFI CFH C4B C4A C3
2 negative regulation of endopeptidase activity GO:0010951 10.06 COL4A3 C4B C4A C3
3 complement activation, classical pathway GO:0006958 9.93 C1QC C3 C4A C4B CFI CR1
4 immune system process GO:0002376 9.92 C1QC C3 C4A C4B CD79A CFH
5 complement activation, alternative pathway GO:0006957 9.86 CR1 CFHR5 CFH C3
6 glomerular basement membrane development GO:0032836 9.85 NPHS1 COL4A4 COL4A3
7 cytolysis by host of symbiont cells GO:0051838 9.78 CFHR5 APOL1
8 positive regulation of activation of membrane attack complex GO:0001970 9.73 CR1 C3
9 positive regulation of apoptotic cell clearance GO:2000427 9.56 CCL2 C4B C4A C3
10 complement activation GO:0006956 9.36 CFI CFHR5 CFH C4B C4A C3

Molecular functions related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent conferring tensile strength GO:0030020 9.63 COL4A5 COL4A4 COL4A3
2 endopeptidase inhibitor activity GO:0004866 9.43 C4B C4A C3
3 complement component C3b binding GO:0001851 9.1 CR1 CFHR5 CFH
Sources

Sources for Glomerulonephritis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....